# Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes

Study · id `cardio:ct-nct04365400` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04365400](<https://clinicaltrials.gov/study/NCT04365400>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04365400

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 233 participants.

## Technical summary

Registry record NCT04365400. Randomized; double masking; primary purpose treatment. Start 2020-10-13 (actual); primary completion 2022-05-03 (actual). Results posted on 2023-06-01.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 233 participants (enrolled count; ClinicalTrials.gov record NCT04365400, source copy `cardio:ctgov-nct04365400-2023-06-12`, retrieved 2026-10-26)
- Started: 2020-10-13 (actual) (ClinicalTrials.gov record NCT04365400, source copy `cardio:ctgov-nct04365400-2023-06-12`, retrieved 2026-10-26)
- Primary completion: 2022-05-03 (actual) (ClinicalTrials.gov record NCT04365400, source copy `cardio:ctgov-nct04365400-2023-06-12`, retrieved 2026-10-26)
- Completion: 2022-05-03 (actual) (ClinicalTrials.gov record NCT04365400, source copy `cardio:ctgov-nct04365400-2023-06-12`, retrieved 2026-10-26)
- Results first posted: 2023-06-01 (ClinicalTrials.gov record NCT04365400, source copy `cardio:ctgov-nct04365400-2023-06-12`, retrieved 2026-10-26)
- Countries: United States; Georgia; Germany; Israel; Latvia; Switzerland (ClinicalTrials.gov record NCT04365400, source copy `cardio:ctgov-nct04365400-2023-06-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04365400-2023-06-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
- Acronym: TRIAGE
- Condition: Hypertriglyceridemia
- Condition: Type 2 Diabetes
- Intervention (Drug): DS102
- Intervention (Drug): Placebo
- Lead sponsor: Afimmune
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: abef57b324f85366cf234e51dc8df8b101a28059d84b679b210e140bfc43f005
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
